Pfizer and Qiagen subsidiary DxS have entered into an agreement to develop a companion diagnostic test kit for PF-04948568, an immunotherapy vaccine in development to treat brain tumours.
Pfizer and Celldex Therapeutics entered into an agreement in April 2008 to grant Pfizer exclusive worldwide licence to PF-04948568 (CDX-110), which is in Phase II clinical development for the treatment of newly diagnosed glioblastoma multiforme (GBM) brain tumours.
The EGFRvIII companion diagnostic will be a real-time PCR assay used to detect EGFRvIII RNA in tumour tissue.
Qiagen vice-president of personalised healthcare Stephen Little said that the company looks forward to collaborating with QIAGEN’s DxS unit in the development of this important diagnostic tool.
“This important diagnostic tool could potentially help physicians better define the most appropriate treatment for patients who suffer from GBM,” Little said.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData